Ty Kiser
Concepts (439)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anticoagulants | 13 | 2022 | 559 | 3.160 |
Why?
| Anti-Bacterial Agents | 15 | 2024 | 1510 | 2.700 |
Why?
| Teicoplanin | 3 | 2024 | 17 | 2.500 |
Why?
| Heparin | 10 | 2019 | 230 | 2.290 |
Why?
| Venous Thromboembolism | 5 | 2022 | 234 | 2.240 |
Why?
| Vancomycin | 6 | 2024 | 79 | 2.120 |
Why?
| Thrombocytopenia | 9 | 2020 | 185 | 2.090 |
Why?
| Hirudins | 8 | 2020 | 46 | 2.080 |
Why?
| Critical Illness | 19 | 2022 | 662 | 1.960 |
Why?
| Voriconazole | 3 | 2019 | 24 | 1.810 |
Why?
| Peptide Fragments | 7 | 2020 | 702 | 1.690 |
Why?
| Triazoles | 3 | 2019 | 134 | 1.680 |
Why?
| Antithrombins | 4 | 2020 | 51 | 1.680 |
Why?
| Peritonitis | 2 | 2024 | 79 | 1.630 |
Why?
| Peritoneal Dialysis | 2 | 2024 | 84 | 1.550 |
Why?
| Intensive Care Units | 18 | 2022 | 635 | 1.540 |
Why?
| Hemofiltration | 4 | 2017 | 31 | 1.460 |
Why?
| Thrombosis | 4 | 2021 | 309 | 1.420 |
Why?
| Drug Packaging | 3 | 2016 | 44 | 1.410 |
Why?
| Thrombin | 3 | 2020 | 143 | 1.390 |
Why?
| Antifungal Agents | 4 | 2021 | 134 | 1.320 |
Why?
| Thromboembolism | 3 | 2021 | 99 | 1.240 |
Why?
| Pipecolic Acids | 4 | 2020 | 22 | 1.230 |
Why?
| Fibrinolytic Agents | 4 | 2018 | 238 | 1.220 |
Why?
| Microbial Sensitivity Tests | 6 | 2021 | 302 | 1.180 |
Why?
| Pulmonary Embolism | 3 | 2019 | 183 | 1.170 |
Why?
| Tissue Plasminogen Activator | 2 | 2018 | 231 | 1.150 |
Why?
| Factor Xa Inhibitors | 2 | 2018 | 138 | 1.130 |
Why?
| beta-Cyclodextrins | 2 | 2015 | 31 | 1.040 |
Why?
| Kidney Diseases | 5 | 2021 | 439 | 1.020 |
Why?
| Middle Aged | 48 | 2022 | 27617 | 1.020 |
Why?
| Hospitalization | 7 | 2023 | 1785 | 0.950 |
Why?
| Syringes | 3 | 2016 | 37 | 0.940 |
Why?
| Renal Replacement Therapy | 4 | 2022 | 70 | 0.940 |
Why?
| Retrospective Studies | 33 | 2023 | 12978 | 0.920 |
Why?
| Pulmonary Disease, Chronic Obstructive | 3 | 2019 | 1137 | 0.910 |
Why?
| Invasive Fungal Infections | 2 | 2021 | 10 | 0.890 |
Why?
| Factor Xa | 2 | 2021 | 31 | 0.880 |
Why?
| Aged | 33 | 2024 | 19657 | 0.870 |
Why?
| Humans | 91 | 2024 | 118972 | 0.860 |
Why?
| Dalteparin | 2 | 2020 | 9 | 0.860 |
Why?
| Drug Stability | 4 | 2016 | 153 | 0.840 |
Why?
| Drug Monitoring | 4 | 2017 | 187 | 0.830 |
Why?
| Nephrologists | 1 | 2021 | 13 | 0.810 |
Why?
| Partial Thromboplastin Time | 5 | 2014 | 52 | 0.810 |
Why?
| Gram-Positive Bacterial Infections | 2 | 2020 | 67 | 0.800 |
Why?
| Recombinant Proteins | 10 | 2021 | 1308 | 0.800 |
Why?
| Hospital Mortality | 5 | 2020 | 814 | 0.790 |
Why?
| Atrial Fibrillation | 2 | 2022 | 338 | 0.780 |
Why?
| Adrenal Cortex Hormones | 2 | 2015 | 521 | 0.770 |
Why?
| Blood Coagulation Tests | 3 | 2016 | 58 | 0.770 |
Why?
| Adult | 36 | 2024 | 31512 | 0.770 |
Why?
| Female | 51 | 2024 | 61564 | 0.740 |
Why?
| Pseudomonas Infections | 2 | 2013 | 193 | 0.730 |
Why?
| Male | 51 | 2021 | 57801 | 0.730 |
Why?
| Gram-Positive Bacteria | 1 | 2020 | 47 | 0.730 |
Why?
| Dose-Response Relationship, Drug | 11 | 2019 | 1945 | 0.720 |
Why?
| Kidney Failure, Chronic | 3 | 2020 | 516 | 0.720 |
Why?
| Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 15 | 0.710 |
Why?
| Antiviral Agents | 3 | 2020 | 654 | 0.700 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2021 | 156 | 0.690 |
Why?
| Obesity, Morbid | 1 | 2022 | 197 | 0.690 |
Why?
| Cold Temperature | 2 | 2016 | 132 | 0.680 |
Why?
| Diabetic Ketoacidosis | 1 | 2021 | 168 | 0.680 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2018 | 30 | 0.670 |
Why?
| Macrolides | 1 | 2019 | 57 | 0.670 |
Why?
| Nitriles | 1 | 2019 | 155 | 0.650 |
Why?
| Dexmedetomidine | 4 | 2014 | 52 | 0.640 |
Why?
| Hemorrhage | 6 | 2022 | 623 | 0.640 |
Why?
| Pulmonary Ventilation | 1 | 2018 | 71 | 0.640 |
Why?
| Critical Care | 10 | 2021 | 492 | 0.640 |
Why?
| Hepatorenal Syndrome | 2 | 2009 | 14 | 0.630 |
Why?
| Anticonvulsants | 2 | 2017 | 184 | 0.630 |
Why?
| Glomerular Filtration Rate | 1 | 2021 | 683 | 0.620 |
Why?
| Blood Transfusion | 2 | 2020 | 306 | 0.620 |
Why?
| Lung Transplantation | 3 | 2020 | 263 | 0.610 |
Why?
| Piracetam | 1 | 2017 | 15 | 0.610 |
Why?
| Treatment Outcome | 19 | 2022 | 9342 | 0.600 |
Why?
| Ribavirin | 2 | 2020 | 88 | 0.590 |
Why?
| Glass | 1 | 2016 | 44 | 0.580 |
Why?
| Intracranial Hemorrhages | 1 | 2017 | 77 | 0.580 |
Why?
| Hypnotics and Sedatives | 4 | 2014 | 136 | 0.580 |
Why?
| Thiocyanates | 1 | 2016 | 29 | 0.570 |
Why?
| Thiosulfates | 1 | 2016 | 19 | 0.570 |
Why?
| Nitroprusside | 1 | 2016 | 88 | 0.570 |
Why?
| Neoplasms | 3 | 2020 | 2179 | 0.570 |
Why?
| Freezing | 1 | 2016 | 87 | 0.560 |
Why?
| Infusions, Intravenous | 6 | 2020 | 380 | 0.540 |
Why?
| Cyclodextrins | 1 | 2015 | 15 | 0.540 |
Why?
| Cardiopulmonary Bypass | 2 | 2016 | 203 | 0.530 |
Why?
| Cerebral Hemorrhage | 1 | 2016 | 100 | 0.530 |
Why?
| Pyridines | 1 | 2019 | 440 | 0.530 |
Why?
| Curriculum | 2 | 2021 | 910 | 0.530 |
Why?
| Aged, 80 and over | 13 | 2022 | 6561 | 0.520 |
Why?
| Dronabinol | 1 | 2016 | 121 | 0.520 |
Why?
| Therapeutics | 1 | 2015 | 12 | 0.520 |
Why?
| Vasodilator Agents | 2 | 2016 | 328 | 0.510 |
Why?
| Antidotes | 1 | 2016 | 126 | 0.500 |
Why?
| Kidney | 2 | 2021 | 1353 | 0.500 |
Why?
| Stroke | 2 | 2022 | 1047 | 0.490 |
Why?
| Osmotic Pressure | 1 | 2014 | 32 | 0.480 |
Why?
| Vasoconstriction | 2 | 2023 | 213 | 0.480 |
Why?
| Methylprednisolone | 1 | 2014 | 84 | 0.480 |
Why?
| Cohort Studies | 14 | 2021 | 5116 | 0.480 |
Why?
| Respiratory Insufficiency | 3 | 2022 | 290 | 0.450 |
Why?
| Arginine | 4 | 2020 | 249 | 0.430 |
Why?
| Ganciclovir | 1 | 2012 | 46 | 0.420 |
Why?
| Pneumonia, Bacterial | 1 | 2013 | 110 | 0.420 |
Why?
| Multivariate Analysis | 5 | 2017 | 1474 | 0.420 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 387 | 0.420 |
Why?
| Administration, Oral | 4 | 2022 | 756 | 0.410 |
Why?
| Pseudomonas aeruginosa | 2 | 2013 | 305 | 0.410 |
Why?
| Pharmacies | 2 | 2021 | 31 | 0.400 |
Why?
| Pharmacy | 2 | 2021 | 30 | 0.400 |
Why?
| Empirical Research | 1 | 2011 | 25 | 0.390 |
Why?
| Substance Withdrawal Syndrome | 3 | 2022 | 157 | 0.390 |
Why?
| Acute Kidney Injury | 4 | 2018 | 709 | 0.390 |
Why?
| Nomograms | 1 | 2011 | 48 | 0.380 |
Why?
| Drug Resistance, Multiple | 1 | 2010 | 19 | 0.380 |
Why?
| Academic Medical Centers | 3 | 2019 | 422 | 0.370 |
Why?
| Sulfonamides | 4 | 2020 | 445 | 0.370 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 187 | 0.360 |
Why?
| Time Factors | 7 | 2018 | 6412 | 0.350 |
Why?
| Burns | 2 | 2018 | 247 | 0.340 |
Why?
| Drug Therapy, Combination | 5 | 2021 | 965 | 0.330 |
Why?
| Students, Pharmacy | 2 | 2021 | 99 | 0.320 |
Why?
| Rivaroxaban | 2 | 2022 | 208 | 0.310 |
Why?
| Thrombin Time | 2 | 2020 | 11 | 0.310 |
Why?
| Daptomycin | 2 | 2021 | 19 | 0.310 |
Why?
| Patient Discharge | 3 | 2018 | 796 | 0.310 |
Why?
| Polypropylenes | 1 | 2007 | 17 | 0.310 |
Why?
| Sympathomimetics | 1 | 2007 | 26 | 0.300 |
Why?
| Phenylephrine | 1 | 2007 | 85 | 0.300 |
Why?
| Administration, Intravenous | 3 | 2017 | 136 | 0.300 |
Why?
| Expectorants | 1 | 2007 | 24 | 0.300 |
Why?
| Shock, Septic | 2 | 2022 | 187 | 0.300 |
Why?
| Pharmacoepidemiology | 2 | 2019 | 21 | 0.300 |
Why?
| Drug Storage | 3 | 2016 | 59 | 0.290 |
Why?
| Anesthetics | 1 | 2007 | 58 | 0.290 |
Why?
| Drug Compounding | 2 | 2017 | 90 | 0.290 |
Why?
| Lorazepam | 3 | 2014 | 24 | 0.290 |
Why?
| Levofloxacin | 1 | 2006 | 22 | 0.280 |
Why?
| Ofloxacin | 1 | 2006 | 23 | 0.280 |
Why?
| Prospective Studies | 7 | 2022 | 6471 | 0.280 |
Why?
| Respiration | 1 | 2007 | 183 | 0.280 |
Why?
| Acetylcysteine | 1 | 2007 | 148 | 0.280 |
Why?
| Alcoholism | 2 | 2023 | 717 | 0.280 |
Why?
| Gentamicins | 2 | 2023 | 42 | 0.280 |
Why?
| Pneumonia | 3 | 2023 | 592 | 0.270 |
Why?
| Models, Biological | 1 | 2013 | 1715 | 0.270 |
Why?
| Vasoconstrictor Agents | 2 | 2023 | 122 | 0.270 |
Why?
| Young Adult | 8 | 2019 | 10793 | 0.270 |
Why?
| Arginine Vasopressin | 1 | 2005 | 47 | 0.270 |
Why?
| Area Under Curve | 4 | 2019 | 296 | 0.270 |
Why?
| Octreotide | 1 | 2005 | 27 | 0.260 |
Why?
| Neuromuscular Blocking Agents | 2 | 2018 | 23 | 0.260 |
Why?
| Length of Stay | 4 | 2019 | 1032 | 0.260 |
Why?
| Cross-Over Studies | 2 | 2020 | 456 | 0.260 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2021 | 3360 | 0.260 |
Why?
| Warfarin | 2 | 2022 | 139 | 0.250 |
Why?
| Pharmacists | 4 | 2021 | 238 | 0.240 |
Why?
| Hydrogen-Ion Concentration | 2 | 2016 | 536 | 0.240 |
Why?
| Temperature | 3 | 2016 | 622 | 0.240 |
Why?
| Blood Coagulation | 2 | 2016 | 219 | 0.230 |
Why?
| Liver Diseases | 1 | 2006 | 282 | 0.230 |
Why?
| Saline Solution, Hypertonic | 1 | 2023 | 56 | 0.220 |
Why?
| Risk Factors | 7 | 2023 | 9000 | 0.220 |
Why?
| Incidence | 2 | 2020 | 2424 | 0.220 |
Why?
| Adolescent | 9 | 2022 | 18480 | 0.220 |
Why?
| Ethanol | 3 | 2022 | 575 | 0.220 |
Why?
| Liver Transplantation | 1 | 2009 | 847 | 0.210 |
Why?
| Thinness | 1 | 2022 | 91 | 0.210 |
Why?
| Sexual Harassment | 1 | 2021 | 26 | 0.200 |
Why?
| Aspergillosis | 1 | 2021 | 24 | 0.200 |
Why?
| Prothrombin | 1 | 2021 | 21 | 0.200 |
Why?
| Candidiasis | 1 | 2021 | 59 | 0.200 |
Why?
| Statistics, Nonparametric | 3 | 2017 | 403 | 0.200 |
Why?
| Cephalosporins | 1 | 2021 | 27 | 0.200 |
Why?
| Community Pharmacy Services | 1 | 2021 | 46 | 0.190 |
Why?
| Pharmaceutical Services | 1 | 2021 | 79 | 0.190 |
Why?
| Drug Administration Schedule | 3 | 2018 | 736 | 0.190 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2016 | 490 | 0.190 |
Why?
| Ascitic Fluid | 1 | 2020 | 15 | 0.190 |
Why?
| Vasoplegia | 1 | 2020 | 2 | 0.190 |
Why?
| Noninvasive Ventilation | 1 | 2020 | 30 | 0.190 |
Why?
| Salvage Therapy | 1 | 2021 | 130 | 0.180 |
Why?
| Platelet Count | 1 | 2020 | 83 | 0.180 |
Why?
| Monte Carlo Method | 2 | 2013 | 146 | 0.180 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 240 | 0.180 |
Why?
| Hydroxocobalamin | 1 | 2020 | 26 | 0.180 |
Why?
| Respiratory Syncytial Virus Infections | 1 | 2020 | 99 | 0.170 |
Why?
| Speech Therapy | 1 | 2019 | 20 | 0.170 |
Why?
| Anti-Infective Agents | 1 | 2022 | 227 | 0.170 |
Why?
| Body Weight | 2 | 2021 | 934 | 0.170 |
Why?
| Hemostasis | 1 | 2019 | 70 | 0.160 |
Why?
| Intubation, Intratracheal | 1 | 2020 | 226 | 0.160 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 190 | 0.160 |
Why?
| Vecuronium Bromide | 1 | 2018 | 6 | 0.160 |
Why?
| Coronary Circulation | 1 | 2018 | 121 | 0.160 |
Why?
| Asthma | 2 | 2022 | 2158 | 0.160 |
Why?
| Atracurium | 1 | 2018 | 13 | 0.160 |
Why?
| Heart Failure, Systolic | 1 | 2018 | 20 | 0.160 |
Why?
| Heart Failure, Diastolic | 1 | 2018 | 21 | 0.160 |
Why?
| Gastric Emptying | 2 | 2008 | 40 | 0.160 |
Why?
| Calcineurin Inhibitors | 1 | 2018 | 61 | 0.160 |
Why?
| Kidney Transplantation | 2 | 2018 | 585 | 0.160 |
Why?
| Logistic Models | 3 | 2017 | 1901 | 0.160 |
Why?
| Cardiologists | 1 | 2018 | 40 | 0.160 |
Why?
| Occupational Therapy | 1 | 2019 | 73 | 0.160 |
Why?
| Comparative Effectiveness Research | 1 | 2018 | 132 | 0.160 |
Why?
| Gastrointestinal Agents | 2 | 2008 | 58 | 0.160 |
Why?
| Antibodies, Bacterial | 1 | 2018 | 126 | 0.150 |
Why?
| Polyneuropathies | 1 | 2017 | 50 | 0.150 |
Why?
| Education, Pharmacy, Graduate | 1 | 2017 | 21 | 0.150 |
Why?
| Self-Directed Learning as Topic | 1 | 2017 | 3 | 0.150 |
Why?
| Immunity, Humoral | 1 | 2018 | 117 | 0.150 |
Why?
| Immunotherapy | 1 | 2021 | 493 | 0.150 |
Why?
| Pharmaceutical Solutions | 1 | 2016 | 14 | 0.150 |
Why?
| Databases, Factual | 2 | 2019 | 1231 | 0.150 |
Why?
| Propensity Score | 2 | 2017 | 242 | 0.150 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 667 | 0.150 |
Why?
| Disease-Free Survival | 1 | 2018 | 649 | 0.150 |
Why?
| Career Mobility | 1 | 2017 | 66 | 0.150 |
Why?
| Chromatography, Reverse-Phase | 1 | 2016 | 25 | 0.150 |
Why?
| Neurosurgical Procedures | 1 | 2018 | 164 | 0.140 |
Why?
| Staphylococcal Infections | 1 | 2021 | 346 | 0.140 |
Why?
| Pneumococcal Vaccines | 1 | 2018 | 140 | 0.140 |
Why?
| Intensive Care Units, Neonatal | 1 | 2019 | 178 | 0.140 |
Why?
| Transplant Recipients | 2 | 2018 | 148 | 0.140 |
Why?
| Capsules | 1 | 2016 | 35 | 0.140 |
Why?
| Enteral Nutrition | 2 | 2008 | 170 | 0.140 |
Why?
| Patient Readmission | 2 | 2019 | 634 | 0.140 |
Why?
| Solubility | 1 | 2016 | 235 | 0.140 |
Why?
| Physical Therapy Modalities | 1 | 2019 | 274 | 0.140 |
Why?
| Psychotropic Drugs | 1 | 2016 | 58 | 0.140 |
Why?
| Cholestyramine Resin | 1 | 2015 | 7 | 0.140 |
Why?
| Opioid-Related Disorders | 1 | 2023 | 417 | 0.140 |
Why?
| Drug Prescriptions | 1 | 2018 | 248 | 0.140 |
Why?
| Regression Analysis | 2 | 2016 | 983 | 0.140 |
Why?
| Calibration | 1 | 2016 | 135 | 0.130 |
Why?
| Pharmacokinetics | 1 | 2015 | 27 | 0.130 |
Why?
| Isoxazoles | 1 | 2015 | 56 | 0.130 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 304 | 0.130 |
Why?
| Internship, Nonmedical | 1 | 2015 | 17 | 0.130 |
Why?
| Societies, Pharmaceutical | 1 | 2015 | 28 | 0.130 |
Why?
| Ventricular Function, Left | 1 | 2018 | 468 | 0.130 |
Why?
| Double-Blind Method | 4 | 2014 | 1687 | 0.130 |
Why?
| Pyridones | 1 | 2016 | 119 | 0.130 |
Why?
| Enterocolitis, Pseudomembranous | 1 | 2014 | 24 | 0.130 |
Why?
| Administration, Inhalation | 1 | 2016 | 656 | 0.130 |
Why?
| Prosthesis-Related Infections | 1 | 2015 | 73 | 0.130 |
Why?
| Anti-Ulcer Agents | 1 | 2014 | 16 | 0.130 |
Why?
| Peptic Ulcer | 1 | 2014 | 14 | 0.130 |
Why?
| Histamine H2 Antagonists | 1 | 2014 | 31 | 0.130 |
Why?
| Teaching | 1 | 2017 | 236 | 0.120 |
Why?
| United States | 6 | 2019 | 12555 | 0.120 |
Why?
| Diltiazem | 1 | 2014 | 22 | 0.120 |
Why?
| Dabigatran | 1 | 2014 | 26 | 0.120 |
Why?
| beta-Alanine | 1 | 2014 | 20 | 0.120 |
Why?
| Tandem Mass Spectrometry | 1 | 2016 | 421 | 0.120 |
Why?
| Thromboplastin | 1 | 2014 | 68 | 0.120 |
Why?
| Drug Dosage Calculations | 1 | 2014 | 21 | 0.120 |
Why?
| Seizures | 1 | 2017 | 345 | 0.120 |
Why?
| Immunoglobulin G | 1 | 2018 | 788 | 0.120 |
Why?
| Benzodiazepines | 1 | 2014 | 122 | 0.120 |
Why?
| Proton Pump Inhibitors | 1 | 2014 | 98 | 0.120 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2014 | 109 | 0.120 |
Why?
| Midazolam | 1 | 2013 | 49 | 0.120 |
Why?
| Guidelines as Topic | 1 | 2015 | 262 | 0.110 |
Why?
| Patient Acceptance of Health Care | 1 | 2019 | 687 | 0.110 |
Why?
| Community-Acquired Infections | 1 | 2014 | 143 | 0.110 |
Why?
| Benzimidazoles | 1 | 2014 | 140 | 0.110 |
Why?
| Antirheumatic Agents | 1 | 2015 | 254 | 0.110 |
Why?
| Medication Adherence | 1 | 2018 | 556 | 0.110 |
Why?
| Conscious Sedation | 1 | 2013 | 79 | 0.110 |
Why?
| Oxazolidinones | 1 | 2012 | 14 | 0.110 |
Why?
| Antibiotic Prophylaxis | 1 | 2014 | 100 | 0.110 |
Why?
| Sirolimus | 1 | 2014 | 195 | 0.110 |
Why?
| Motivation | 1 | 2017 | 506 | 0.110 |
Why?
| Acetamides | 1 | 2012 | 26 | 0.110 |
Why?
| Learning | 1 | 2017 | 374 | 0.110 |
Why?
| APACHE | 2 | 2010 | 61 | 0.110 |
Why?
| Pyrazoles | 1 | 2016 | 363 | 0.110 |
Why?
| Coronary Artery Bypass | 1 | 2014 | 209 | 0.110 |
Why?
| Colorado | 3 | 2017 | 4196 | 0.110 |
Why?
| Mental Recall | 1 | 2013 | 180 | 0.110 |
Why?
| Lipids | 1 | 2016 | 607 | 0.110 |
Why?
| Treatment Failure | 1 | 2013 | 341 | 0.110 |
Why?
| Patient Selection | 1 | 2016 | 676 | 0.110 |
Why?
| Acute Disease | 1 | 2015 | 940 | 0.110 |
Why?
| Metabolic Clearance Rate | 1 | 2012 | 113 | 0.100 |
Why?
| Fellowships and Scholarships | 1 | 2015 | 250 | 0.100 |
Why?
| Metoclopramide | 2 | 2008 | 17 | 0.100 |
Why?
| Erythromycin | 2 | 2008 | 25 | 0.100 |
Why?
| Injections, Intravenous | 1 | 2012 | 210 | 0.100 |
Why?
| Disease Progression | 2 | 2020 | 2490 | 0.100 |
Why?
| Research | 1 | 2015 | 411 | 0.100 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2014 | 189 | 0.100 |
Why?
| Surgical Wound Infection | 1 | 2014 | 251 | 0.100 |
Why?
| Neuromuscular Blockade | 1 | 2011 | 23 | 0.100 |
Why?
| Polymorphism, Genetic | 1 | 2014 | 642 | 0.100 |
Why?
| Imipenem | 1 | 2010 | 17 | 0.100 |
Why?
| Genes, Regulator | 1 | 2010 | 33 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2014 | 465 | 0.090 |
Why?
| Glucocorticoids | 1 | 2015 | 545 | 0.090 |
Why?
| Drug Resistance | 1 | 2011 | 167 | 0.090 |
Why?
| Hypothermia, Induced | 1 | 2011 | 68 | 0.090 |
Why?
| Pharmaceutical Vehicles | 1 | 2009 | 11 | 0.090 |
Why?
| Propylene Glycol | 1 | 2009 | 9 | 0.090 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 332 | 0.090 |
Why?
| Respiration, Artificial | 3 | 2020 | 545 | 0.090 |
Why?
| Protein C | 1 | 2010 | 44 | 0.090 |
Why?
| Aortic Valve | 1 | 2014 | 401 | 0.090 |
Why?
| Risk Assessment | 2 | 2016 | 3057 | 0.090 |
Why?
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 39 | 0.090 |
Why?
| Biomedical Research | 1 | 2015 | 612 | 0.090 |
Why?
| Aging | 1 | 2019 | 1670 | 0.080 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 1795 | 0.080 |
Why?
| Biomarkers | 2 | 2016 | 3588 | 0.080 |
Why?
| Acetaminophen | 2 | 2008 | 244 | 0.080 |
Why?
| Monitoring, Physiologic | 1 | 2010 | 271 | 0.080 |
Why?
| Certification | 1 | 2009 | 99 | 0.080 |
Why?
| Kidney Function Tests | 1 | 2008 | 164 | 0.080 |
Why?
| Infant, Newborn | 1 | 2019 | 5255 | 0.080 |
Why?
| Standard of Care | 2 | 2021 | 63 | 0.080 |
Why?
| Liver Cirrhosis | 1 | 2009 | 245 | 0.080 |
Why?
| Lung Diseases | 1 | 2014 | 718 | 0.080 |
Why?
| Cost Control | 1 | 2007 | 44 | 0.080 |
Why?
| Databases as Topic | 1 | 2007 | 73 | 0.070 |
Why?
| Emergency Service, Hospital | 1 | 2018 | 1864 | 0.070 |
Why?
| Renal Dialysis | 1 | 2010 | 378 | 0.070 |
Why?
| Propofol | 1 | 2007 | 49 | 0.070 |
Why?
| Fentanyl | 1 | 2007 | 70 | 0.070 |
Why?
| Creatinine | 1 | 2008 | 491 | 0.070 |
Why?
| Analgesics, Non-Narcotic | 1 | 2008 | 116 | 0.070 |
Why?
| Half-Life | 1 | 2006 | 147 | 0.070 |
Why?
| Schools, Pharmacy | 2 | 2017 | 52 | 0.070 |
Why?
| Practice Patterns, Physicians' | 1 | 2014 | 1200 | 0.070 |
Why?
| Antidiuretic Agents | 1 | 2005 | 7 | 0.070 |
Why?
| Platelet Activation | 1 | 2005 | 70 | 0.070 |
Why?
| Platelet Aggregation | 1 | 2005 | 97 | 0.070 |
Why?
| Chromatography, Liquid | 1 | 2007 | 355 | 0.070 |
Why?
| Severity of Illness Index | 1 | 2013 | 2674 | 0.070 |
Why?
| Gene Expression Regulation | 1 | 2014 | 2445 | 0.060 |
Why?
| Practice Guidelines as Topic | 1 | 2012 | 1440 | 0.060 |
Why?
| Penicillins | 1 | 2023 | 50 | 0.060 |
Why?
| DNA | 1 | 2010 | 1388 | 0.060 |
Why?
| Animals | 2 | 2016 | 33381 | 0.060 |
Why?
| Transcription Factors | 1 | 2010 | 1570 | 0.050 |
Why?
| Minnesota | 1 | 2022 | 137 | 0.050 |
Why?
| Vasopressins | 1 | 2022 | 64 | 0.050 |
Why?
| Computer Simulation | 1 | 2006 | 922 | 0.050 |
Why?
| Norepinephrine | 1 | 2022 | 212 | 0.050 |
Why?
| Serum Albumin | 1 | 2022 | 146 | 0.050 |
Why?
| Critical Care Outcomes | 1 | 2020 | 12 | 0.050 |
Why?
| Status Asthmaticus | 1 | 2020 | 11 | 0.050 |
Why?
| Gender Identity | 1 | 2021 | 102 | 0.050 |
Why?
| Surveys and Questionnaires | 3 | 2021 | 4708 | 0.050 |
Why?
| Polyphosphates | 1 | 2020 | 32 | 0.050 |
Why?
| Hypertension, Pulmonary | 1 | 2012 | 1794 | 0.050 |
Why?
| Rifampin | 1 | 2021 | 69 | 0.050 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 245 | 0.050 |
Why?
| Drug Synergism | 1 | 2021 | 339 | 0.050 |
Why?
| Sepsis | 2 | 2020 | 531 | 0.050 |
Why?
| Methylene Blue | 1 | 2020 | 24 | 0.050 |
Why?
| Pilot Projects | 2 | 2015 | 1419 | 0.040 |
Why?
| Mutation | 1 | 2010 | 3457 | 0.040 |
Why?
| Hypersensitivity | 1 | 2023 | 268 | 0.040 |
Why?
| Bacteremia | 1 | 2021 | 161 | 0.040 |
Why?
| Interprofessional Relations | 1 | 2021 | 261 | 0.040 |
Why?
| Sex Factors | 2 | 2018 | 1781 | 0.040 |
Why?
| Vascular Resistance | 1 | 2020 | 356 | 0.040 |
Why?
| Hospitals, Rural | 1 | 2018 | 29 | 0.040 |
Why?
| Patient Satisfaction | 1 | 2022 | 610 | 0.040 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 613 | 0.040 |
Why?
| Hospital Charges | 1 | 2017 | 42 | 0.040 |
Why?
| Hospitals, Urban | 1 | 2018 | 129 | 0.040 |
Why?
| Bayes Theorem | 1 | 2019 | 344 | 0.040 |
Why?
| Muscular Diseases | 1 | 2017 | 107 | 0.040 |
Why?
| Venous Thrombosis | 1 | 2019 | 147 | 0.040 |
Why?
| Drug Interactions | 1 | 2018 | 352 | 0.040 |
Why?
| Insurance Coverage | 1 | 2018 | 208 | 0.040 |
Why?
| Problem-Based Learning | 1 | 2017 | 82 | 0.030 |
Why?
| Comorbidity | 1 | 2020 | 1527 | 0.030 |
Why?
| Pharmacology, Clinical | 1 | 2015 | 8 | 0.030 |
Why?
| Risk | 1 | 2018 | 853 | 0.030 |
Why?
| Education, Pharmacy | 1 | 2017 | 130 | 0.030 |
Why?
| Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.030 |
Why?
| Expert Testimony | 1 | 2015 | 56 | 0.030 |
Why?
| Delphi Technique | 1 | 2015 | 164 | 0.030 |
Why?
| Checklist | 1 | 2015 | 81 | 0.030 |
Why?
| Cytochrome P-450 CYP2C8 | 1 | 2014 | 15 | 0.030 |
Why?
| Educational Measurement | 1 | 2017 | 289 | 0.030 |
Why?
| Bradycardia | 1 | 2014 | 49 | 0.030 |
Why?
| Pharmacy Service, Hospital | 1 | 2015 | 86 | 0.030 |
Why?
| Infusions, Parenteral | 1 | 2014 | 37 | 0.030 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 43 | 0.030 |
Why?
| Everolimus | 1 | 2014 | 64 | 0.030 |
Why?
| Stress Disorders, Traumatic, Acute | 1 | 2013 | 8 | 0.030 |
Why?
| Receptors, Steroid | 1 | 2014 | 54 | 0.030 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2014 | 60 | 0.030 |
Why?
| Cross-Sectional Studies | 2 | 2014 | 4552 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2014 | 360 | 0.030 |
Why?
| Tissue Distribution | 1 | 2014 | 334 | 0.030 |
Why?
| Demography | 1 | 2014 | 274 | 0.030 |
Why?
| Hypotension | 1 | 2014 | 120 | 0.030 |
Why?
| Cerebral Ventriculitis | 1 | 2012 | 3 | 0.030 |
Why?
| Linezolid | 1 | 2012 | 16 | 0.030 |
Why?
| Vancomycin Resistance | 1 | 2012 | 15 | 0.030 |
Why?
| Injections, Intraventricular | 1 | 2012 | 73 | 0.030 |
Why?
| Enterococcus faecium | 1 | 2012 | 10 | 0.030 |
Why?
| Healthcare Disparities | 1 | 2018 | 496 | 0.030 |
Why?
| Health Care Surveys | 1 | 2014 | 546 | 0.030 |
Why?
| Drainage | 1 | 2012 | 157 | 0.030 |
Why?
| Stress, Physiological | 1 | 2014 | 415 | 0.020 |
Why?
| Quality of Life | 1 | 2021 | 2366 | 0.020 |
Why?
| Contraindications | 1 | 2010 | 86 | 0.020 |
Why?
| Immunosuppressive Agents | 1 | 2014 | 681 | 0.020 |
Why?
| Governing Board | 1 | 2009 | 7 | 0.020 |
Why?
| Multiple Organ Failure | 1 | 2010 | 150 | 0.020 |
Why?
| Observer Variation | 1 | 2010 | 309 | 0.020 |
Why?
| Diagnostic Errors | 1 | 2010 | 162 | 0.020 |
Why?
| Genotype | 1 | 2014 | 1882 | 0.020 |
Why?
| Specialization | 1 | 2009 | 120 | 0.020 |
Why?
| Dopamine Antagonists | 1 | 2008 | 22 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2010 | 336 | 0.020 |
Why?
| Intubation, Gastrointestinal | 1 | 2008 | 61 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 969 | 0.020 |
Why?
| Anxiety | 1 | 2013 | 845 | 0.020 |
Why?
| Attitude of Health Personnel | 1 | 2014 | 992 | 0.020 |
Why?
| Case-Control Studies | 1 | 2014 | 3171 | 0.020 |
Why?
| Prognosis | 1 | 2014 | 3443 | 0.020 |
Why?
| Depression | 1 | 2013 | 1132 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2014 | 4596 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1868 | 0.020 |
Why?
| Age Factors | 1 | 2009 | 2995 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2010 | 2874 | 0.010 |
Why?
| Clinical Competence | 1 | 2009 | 951 | 0.010 |
Why?
| Physicians | 1 | 2010 | 794 | 0.010 |
Why?
|
|
Kiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|